News
Elite Pharmaceuticals and ECR Launch Second Once-Daily Antihistamine
Elite Pharmaceutical, Inc.'s marketing partner, ECR Pharmaceuticals, has launched Elite's second once-a-day allergy product, under ECR's brand LODRANE 24D, an extended release formulation of brompheniramine maleate and pseudoephedrine HCl.
Lodrane 24D utilizes Elite's proprietary extended release technology to provide once-daily dosing of an effective, low-sedating antihistamine combined with a decongestant. The once-a-day formulation is designed to enhance patient convenience and compliance for those who require chronic allergy therapy. This product and ECR's previously marketed Lodrane 24(R), a once-daily antihistamine-only formulation, were both developed by Elite.
Lodrane 24D will be promoted to healthcare providers in the U.S. by ECR Pharmaceuticals field sales representatives and will be available by prescription through pharmacies. Elite Pharmaceuticals will manufacture the product and will receive a royalty on product revenues. The current U.S. allergy market exceeds $3 billion.
"We are pleased to have worked with Elite Pharmaceuticals to develop products which utilize the firm's extended release drug delivery technology. Lodrane 24 and 24D offer patients therapeutic alternatives, which can better meet their daily needs. Our partnership with Elite has allowed us to provide physicians and patients with products which offer these expanded choices," said E. Claiborne Robins, Jr., President and CEO of ECR Pharmaceuticals.
"This product is another example of how our proprietary extended release technology can be utilized by our partners. Launching Lodrane 24D, the second product we have commercialized with ECR Pharmaceuticals, is another significant milestone validating our drug delivery capabilities," said Bernard Berk, President and CEO of Elite. "We look forward to continuing to build and leverage Elite's proprietary technologies through our product pipeline, partnerships and ventures as we continue to systematically meet the milestones we have set for ourselves."